Jones Trading Starts Spruce Biosciences, Inc. (SPRB) at Buy Jun 8, 2026 04:11PM
Spruce Biosciences presents long-term data for MPS IIIB treatment Jun 8, 2026 04:05PM
Spruce Biosciences, Inc. (SPRB) PT Lowered to $230 at Oppenheimer May 27, 2026 05:50AM
Spruce Biosciences, Inc. (SPRB) PT Lowered to $150 at Citizens After Q1 Results, Model Update May 14, 2026 04:54AM
Spruce Biosciences appoints two VPs to commercial leadership team May 4, 2026 08:03AM


Apr 27, 2026 09:34AM Craig-Hallum Starts Spruce Biosciences, Inc. (SPRB) at Buy
Mar 25, 2026 05:35AM Spruce Biosciences (SPRB) Reiterated at Market Outperform by Citizens; 'Risk Mitigated'
Dec 23, 2025 06:04AM Oppenheimer Starts Spruce Biosciences, Inc. (SPRB) at Outperform
Dec 22, 2025 06:20AM H.C. Wainwright Resumes Spruce Biosciences, Inc. (SPRB) at Buy
Dec 3, 2025 06:39AM Leerink Partners Upgrades Spruce Biosciences, Inc. (SPRB) to Outperform
Nov 11, 2025 04:35AM Spruce Biosciences, Inc. (SPRB) PT Raised to $259 at Citizens
Oct 28, 2025 01:54AM Citizens Upgrades Spruce Biosciences, Inc. (SPRB) to Market Outperform
Oct 21, 2025 02:38PM Spruce Biosciences, Inc. (SPRB) PT Raised to $160 at Leerink Partners
Sep 15, 2025 07:02AM Spruce Biosciences resumes trading on NASDAQ Capital Market
Aug 14, 2025 04:00PM Spruce Biosciences reports positive long-term data for MPS IIIB therapy
Jun 12, 2025 08:17AM Spruce Biosciences (SPRB) Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market
Apr 23, 2025 04:27AM Citizens JMP Reiterates Market Perform Rating on Spruce Biosciences, Inc. (SPRB)
Apr 15, 2025 07:02AM Spruce Biosciences (SPRB) Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B
Dec 11, 2024 08:12AM Spruce Biosciences, Inc. (SPRB) PT Lowered to $1.50 at RBC Capital Following Study Fail
Dec 11, 2024 02:54AM Oppenheimer Downgrades Spruce Biosciences, Inc. (SPRB) to Perform
Dec 11, 2024 02:53AM JMP Securities Downgrades Spruce Biosciences, Inc. (SPRB) to Market Perform
Dec 10, 2024 04:02PM Spruce Biosciences (SPRB) Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH
Dec 10, 2024 04:01PM Spruce Biosciences (SPRB) Halted, News Pending
Dec 2, 2024 06:05AM Oppenheimer Reiterates Outperform Rating on Spruce Biosciences, Inc. (SPRB)
Aug 12, 2024 04:02PM Spruce Biosciences, Inc. (SPRB) Tops Q2 EPS by 10c
Jun 13, 2024 07:37AM Spruce Biosciences, Inc. (SPRB) PT Lowered to $3 at Oppenheimer